The first week of February 2026 will be remembered as the day the pharmaceutical sector’s most famous partnership officially ...

The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its ...

Hims & Hers has a GLP-1 weight loss pill -- and it's the cheapest one out there.

Historical evidence indicates that abrupt market fluctuations can affect any corporation, regardless of its perceived dominance.

Within a single day, the two biggest makers of modern weight-loss drugs signaled different paths for the booming market. Novo ...

Within the span of 19 hours, weight loss drugmakers Novo Nordisk A/S and Eli Lilly & Co. offered wildly divergent views on ...

Eli Lilly stock has soared in the triple digits over three years. Investors are excited about the company’s portfolio of weight loss drugs, which has generated blockbuster revenue. Investors generally ...

Eli Lilly rated SELL: rich valuation priced for perfection, rising GLP-1 competition, pricing pressure, and patent-cliff risk. Click here to read more on LLY stock.

Investors generally don't turn to pharmaceutical stocks with expectations of high growth in a short period of time. Instead, they scoop up these players for their promise of steady gains over the ...